Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.

Pieternella J. Lugtenburg, Alexander R. Lyon, Reinhard Marks, Stefano Luminari

Research output: Contribution to journalArticle

Abstract

The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient's health status to achieve a maximal benefit-risk ratio.

Original languageEnglish
Pages (from-to)1197-1205
Number of pages9
JournalFuture Oncology
Volume15
Issue number11
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Non-Hodgkin's Lymphoma
Comorbidity
Anthracyclines
Health Status
Therapeutics
Geriatric Assessment
Odds Ratio

Keywords

  • cardiac comorbidities
  • elderly
  • frail
  • non-Hodgkin's lymphoma
  • treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age. / Lugtenburg, Pieternella J.; Lyon, Alexander R.; Marks, Reinhard; Luminari, Stefano.

In: Future Oncology, Vol. 15, No. 11, 01.04.2019, p. 1197-1205.

Research output: Contribution to journalArticle

Lugtenburg, Pieternella J. ; Lyon, Alexander R. ; Marks, Reinhard ; Luminari, Stefano. / Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age. In: Future Oncology. 2019 ; Vol. 15, No. 11. pp. 1197-1205.
@article{92a452bd75634f92a801284cf86a9e8a,
title = "Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.",
abstract = "The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient's health status to achieve a maximal benefit-risk ratio.",
keywords = "cardiac comorbidities, elderly, frail, non-Hodgkin's lymphoma, treatment",
author = "Lugtenburg, {Pieternella J.} and Lyon, {Alexander R.} and Reinhard Marks and Stefano Luminari",
year = "2019",
month = "4",
day = "1",
doi = "10.2217/fon-2019-0019",
language = "English",
volume = "15",
pages = "1197--1205",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.

AU - Lugtenburg, Pieternella J.

AU - Lyon, Alexander R.

AU - Marks, Reinhard

AU - Luminari, Stefano

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient's health status to achieve a maximal benefit-risk ratio.

AB - The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient's health status to achieve a maximal benefit-risk ratio.

KW - cardiac comorbidities

KW - elderly

KW - frail

KW - non-Hodgkin's lymphoma

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85064386102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064386102&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0019

DO - 10.2217/fon-2019-0019

M3 - Article

C2 - 30730219

AN - SCOPUS:85064386102

VL - 15

SP - 1197

EP - 1205

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 11

ER -